Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | WT1 vaccine |
| Synonyms | |
| Therapy Description |
Multiple vaccines consisting of a variety of synthetic peptides derived from the human Wilms' Tumor (WT1) Protein used to induce a cytotoxic T-cell lymphocyte response against cells expressing WT1 (PMID: 25699052). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| WT1 vaccine | Multiple vaccines consisting of a variety of synthetic peptides derived from the human Wilms' Tumor (WT1) Protein used to induce a cytotoxic T-cell lymphocyte response against cells expressing WT1 (PMID: 25699052). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01266083 | Phase II | WT1 vaccine | Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | Completed | USA | 0 |
| NCT01827137 | Phase I | WT1 vaccine Lenalidomide Sargramostim | WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation | Completed | USA | 0 |